Stocks TelegraphStocks Telegraph
Stock Ideas

SABS Stock Performance and Key Statistics

NASDAQ : SABS

SAB Biotherapeutics

$3.99
0.18+4.72%
At Close 4:00 PM
68.41
B+ESG ScoreESG Rating

stock performance chart

SABS Fundamental Analysis

Based on recent data, SAB Biotherapeutics, Inc. (SABS) shows an Average True Range (ATR) of 0.28 and an Enterprise Value of -10.07M. Its average trading volume over the past 3 months is 545.01K, indicating liquidity. These fundamental metrics provide insight into SABS's underlying financial health and market activity.

ATR0.28
Enterprise Value-10.07M
Avg Vol (3 Months)545.01K
Avg Vol (10 Days)353.4K

SABS Technical Analysis Indicators

SAB Biotherapeutics, Inc. (SABS) technical indicators as of April 23, 2026: the SMA 20 is 1.94%, SMA 50 at 3.99%, and SMA 200 at 45.08%. The RSI 14 value is 55.51, suggesting its current momentum. These technical analysis signals help assess SABS's price trends and potential future movements.

SMA 201.94%
SMA 503.99%
SMA 20045.08%
RSI 1455.51

SABS Stock Performance Overview

SAB Biotherapeutics, Inc. (SABS) stock performance overview as of April 23, 2026: The 52-week high is $6.6 (currently -37.42% below), and the 52-week low is $1.3 (currently 313% above). Over the past year, SABS's performance is 12.64%, compared to the S&P 500's 24.91% change.

52-Week High6.6
52-Week High Chg-37.42%
52-Week Low1.3
52-Week Low Chg+313.00%
S&P 500 52-Week Chg24.91%

SAB Biotherapeutics, Inc. (SABS) Historical Stock Performance

According to market data, SAB Biotherapeutics, Inc. (SABS) stock's recent performance metrics show that over the last month, SABS is 1.26%, with a Year-to-Date (YTD) performance of 7.22%. Over the past year, the stock has seen a 12.64% change. These figures summarize SABS's price movements across various periods, reflecting its historical returns.

Period1 Week1 MonthQuarterHalf Year1 YearYTD
High4.054.055.155.156.65.15
Low3.683.653.522.11.33.41
Performance+7.22%+1.26%+59.76%+48.52%+12.64%+7.22%

Industry Analysis and Valuation

According to current financial data, SABS stock's P/E (TTM) ratio is 5.54, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.22. Key valuation ratios for SABS, including P/S (N/A), P/B (0.49), and P/FCF (-0.80), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.

ValuationSABSSector MedianIndustry AvgS&P 500
P/E (TTM)5.54-1.22-5.1232.59
P/S (TTM)N/A3.69464.325.98
P/B (TTM)0.490.890.65
P/FCF (TTM)-0.8-5.75-438.6634.75

Frequently Asked Questions

How is SABS price-to-earnings ratio currently?
SABS has a current P/E ratio of 5.54
How are SABS's price-to-sale and price-to-book ratios?
The SABS stock has a trailing twelve month price-to sales (P/S) ratio of N/A while its price-to-book (P/B) value is 0.49.
Is SAB Biotherapeutics, Inc.'s price-to-cashflow ratio high or low?
SABS's price-to-free-cashflow (P/FCF) ratio is -0.8, an indicator that is currently being trending upward.
What's current simple moving average (SMA) for SABS?
Based on SABS's recent bid, its distance from 20 days simple moving average is 1.94%. It is 3.99% apart from 50 days simple moving average, and it is 45.08% apart from 200 days simple moving average.
What is the 52-week price range for SABS?
The 52-week high for SABS is $6.60 which is -37.42% away from the current price level whereas the distance of that from the 52-week low of $1.30 stands at 313%.
An overview of SABS's stock performance: how did it fare?
The performance of SABS stock was not encouraging with most of its significant price indicators in green. SAB Biotherapeutics, Inc.(NASDAQ: SABS) shares have moved upward +4.72% or $0.18 in the latest trading session and have gained 7.22% year-to-date (YTD). The stock has gained nearly 12.64% over the past year. After moving 59.76% over the trailing 3-month period, the stock is 48.52% higher in the 6-month period. Looking at its performance over the shorter term, it'sgained 7.22% a week and 1.26% a month.
What is SABS's 14-day relative strength index (RSI)?
The current 14-day RSI for SABS stock is 55.51. Investors and traders alike rely on the relative strength index, or RSI, as an oscillating indicator. In terms of values, the RSI operates within a range ranging from 0 to 100. A rising RSI line indicates strength in the shares. As the RSI line falls, the opposite occurs. It is possible to examine different time periods when using the RSI indicator. Shorter time frames can cause the RSI to be more volatile. Most traders pay close attention to the marks between 30 and 70 on the RSI scale. When the stock price moves over 70, it is often considered to be an indicator of overbought conditions. Dropping below 30 indicates oversold territory. These levels are often used by traders to forecast stock price reversals.
For SABS, what is the average true range (ATR) for the past two weeks?
ATR stands for Average True Range, which may be useful when traders or investors are assessing technical inventory. Currently, SAB Biotherapeutics, Inc. (SABS) has a 14-day ATR of 0.28.
What is SABS's current enterprise value?
After closing at $3.81 with 9.56M of its shares outstanding, the current enterprise value of SABS is roughly -10.07M.
Over the past year, how has the stock price of SABS changed?
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is up 12.64% when it comes to the percentage price change over the past 52-weeks. The percentage price change came less than that of broader S&P 500 index that came at a fall of 24.91%. SABS stock price is also up 7.22% on its value in year-to-date trading.
What is the average trading volume for SABS shares?
The number outstanding shares of SABS is 9.56M, and of these 72.52% shares are freely available for trading. On average, SABS stock has traded 353.4K shares per day for the past 10 days. A total of 441.58K shares changed hands during the last trading session with the average session volume of 557.74K shares.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph